Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;14(2):255-71.
doi: 10.1111/ajt.12589. Epub 2014 Jan 8.

Diagnosis and management of antibody-mediated rejection: current status and novel approaches

A Djamali  1 , D B Kaufman, T M Ellis, W Zhong, A Matas, M Samaniego
Affiliations
Review

Diagnosis and management of antibody-mediated rejection: current status and novel approaches

A Djamali et al. Am J Transplant. 2014 Feb.

Abstract

Advances in multimodal immunotherapy have significantly reduced acute rejection rates and substantially improved 1-year graft survival following renal transplantation. However, long-term (10-year) survival rates have stagnated over the past decade. Recent studies indicate that antibody-mediated rejection (ABMR) is among the most important barriers to improving long-term outcomes. Improved understanding of the roles of acute and chronic ABMR has evolved in recent years following major progress in the technical ability to detect and quantify recipient anti-HLA antibody production. Additionally, new knowledge of the immunobiology of B cells and plasma cells that pertains to allograft rejection and tolerance has emerged. Still, questions regarding the classification of ABMR, the precision of diagnostic approaches, and the efficacy of various strategies for managing affected patients abound. This review article provides an overview of current thinking and research surrounding the pathophysiology and diagnosis of ABMR, ABMR-related outcomes, ABMR prevention and treatment, as well as possible future directions in treatment.

Keywords: Antibody-mediated rejection; complement C4d; donor-specific antibodies; phenotype.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of donor-specific antibody-mediated endothelial injury in renal allografts. Anti-MHC antibodies may either result in direct injury to the capillary endothelium or in indirect injury via complement fixation or recruitment of inflammatory cells with Fc receptors. In cases with donor-specific antibodies that lack C4d deposition, endothelial injury and cellular recruitment could be important mediators. Poly, polymorphonuclear cell. Reproduced with permission from Farkash and Colvin .
Figure 2
Figure 2
Acute and chronic definitions of ABMR based on C4d positivity. ABMR, antibody-mediated rejection; ATN, acute tubular necrosis; DSA, donor-specific antibodies; IF, immunofluorescence; IFTA, interstitial fibrosis and tubular atrophy; IHC, immunohistochemistry; PTC, peritubular capillary. Reproduced with permission from Mengel et al .
Figure 3
Figure 3
The natural history of phenotype 2 ABMR. ABMR, antibody-mediated rejection; DSA, donor-specific antibodies; IFTA, interstitial fibrosis and tubular atrophy; TG, transplant glomerulopathy. Reproduced with permission from Wiebe et al .
Figure 4
Figure 4
Therapeutic modalities for ABMR. ABMR, antibody-mediated rejection; APC, antigen-presenting cell; IVIG, intravenous immunoglobulins.
See this image and copyright information in PMC

References

    1. Coll E, Crespo M, Solé M. Lessons from cyclosporine monotherapy in renal transplantation: The impact of acute rejection on long-term allograft outcome. Transplant Proc. 2004;36:S114–S116. , et al. (Suppl): - PubMed
    1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605–612. - PubMed
    1. Meier-Kriesche HJ, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378–383. - PubMed
    1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies. Am J Transplant. 2004;4:1289–1295. - PubMed
    1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant. 2011;11:450–462. - PubMed

Publication types